US-based paediatric care company AngelEye Health has shared a ‘strategic vision’ to expand the capabilities of its neonatal intensive care unit (NICU) bedside camera systems.
The company plans to integrate artificial intelligence (AI), computer vision and machine learning (ML) into the camera systems to improve care delivery in NICUs.
Go deeper with GlobalData
Almost 10,000 AngelEye cameras are currently in use across nearly 250 hospitals.
The company said this established infrastructure provides the opportunity for AI-driven solutions to be implemented rapidly.
AngelEye Health CEO Christopher Rand said: “AngelEye has a longstanding commitment to driving innovation in the NICU.
“We are currently in process of integrating AI and computer vision technologies into our camera systems to give them a more active role in patient care.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData“This is just the beginning, as we continue to explore new ways to push boundaries of what’s possible in neonatal care, paving way for cutting-edge solutions that will define the future of NICU.”
AngelEye is using advanced technologies to develop a comprehensive platform designed to improve safety and clinical decision-making while strengthening family connections.
As part of these efforts, the company is implementing the Early Detection Neuromotor Assessments (EDNA) portfolio, which it acquired in July this year, across its network.
EDNA’s AI-driven movement analysis technology enables AngelEye to track early neuromotor risks and other health indicators in newborns, facilitating earlier interventions and better long-term outcomes.
Beyond neuromotor risk detection, AngelEye is exploring various future applications through its research and development, as well as collaborations with third-party researchers.
These applications aim to provide clinicians with a deeper understanding of neonatal health, leading to more informed decision-making and personalised care plans.
The company is also developing AI and ML tools to optimise workflows, reduce administrative burdens and allow clinicians to spend more time on patient care.
